NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed an expansion of its partnership with Maastricht University to develop genetic and epigenetic cancer diagnostics.

Under the terms of the multiyear deal, MDxHealth will collaborate with Maastricht's Faculty of Health, Medicine, and Life Sciences institute and its School for Oncology and Developmental Biology to develop genetic and epigenetic assays for diagnosing, staging, and treating cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.